Search
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.
Categories: Antihypertensive Agents Indicated for HypertensionBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Mixtures: Vaxigrip Tetra, Suspension for Injection in Pre-filled SyringeAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235720] Although aducanumab's approval represents the first drug treatment for Alzheimer's disease, the approval is conditional on further results. … [L34393] In January 2024, Biogen announced that the development and commercialization of aducanumab will be discontinued to prioritize the marketing of [lecanemab], another drug approved for the treatment
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnIt was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Categories: Antihistamines for Systemic UseProducts: ASTEMIZOL TABLETAS POR 10MGFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190486] The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before … [A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18.
Hydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedLacrisertis a formulation of hydroxypropyl cellulose that is used for artificial tears. … syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for
Categories: Compounds used in a research, industrial, or household settingXanthan gum
go.drugbank.com/drugs/DB11253ApprovedXanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions.
Categories: Compounds used in a research, industrial, or household settingBromocriptine
go.drugbank.com/drugs/DB01200ApprovedInvestigationalWithdrawnIn 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use. … [L43942,L43947] It continues to be used for the indications mentioned above.
Categories: Heterocyclic Compounds with 4 or More RingsDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalIt was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use